Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV.

Fiorina L, Paolucci S, Papadimitriou S, Baldanti F.

J Virol Methods. 2012 Sep;184(1-2):103-5. doi: 10.1016/j.jviromet.2012.05.006. Epub 2012 May 18.

PMID:
22613675
2.

Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.

D'Avolio A, De Nicolò A, Cusato J, Ciancio A, Boglione L, Strona S, Cariti G, Troshina G, Caviglia GP, Smedile A, Rizzetto M, Di Perri G.

Antiviral Res. 2013 Oct;100(1):114-9. doi: 10.1016/j.antiviral.2013.07.021. Epub 2013 Aug 8.

3.

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.

Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K.

J Med Virol. 2011 Jun;83(6):1048-57. doi: 10.1002/jmv.22069.

PMID:
21503919
4.

ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.

Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Funk E, Schlaak J, Fishbein D, Masur H, Polis M, Kottilil S.

J Med Virol. 2012 Jul;84(7):1106-14. doi: 10.1002/jmv.23302.

5.

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.

Naggie S, Rallon NI, Benito JM, Morello J, Rodriguez-Novoa S, Clark PJ, Thompson AJ, Shianna KV, Vispo E, McHutchison JG, Goldstein DB, Soriano V.

J Infect Dis. 2012 Feb 1;205(3):376-83. doi: 10.1093/infdis/jir754. Epub 2011 Dec 9.

6.

Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.

Rau M, Stickel F, Russmann S, Manser CN, Becker PP, Weisskopf M, Schmitt J, Dill MT, Dufour JF, Moradpour D, Semela D, Müllhaupt B, Geier A; Swiss Hepatitis C Cohort Study Group (SCCS).

J Hepatol. 2013 Apr;58(4):669-75. doi: 10.1016/j.jhep.2012.11.027. Epub 2012 Nov 27.

7.

Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.

Rallón NI, Morello J, Labarga P, Benito JM, Rodríguez-Nóvoa S, Vispo E, Barreiro P, Castro MÁ, Aguirrebengoa K, Pineda JA, Miralles P, Tellez MJ, Portu J, Miralles C, Ocampo A, Soriano V; Peginterferon Ribavirin Coinfection Team.

Clin Infect Dis. 2011 Dec;53(12):1291-5. doi: 10.1093/cid/cir665. Epub 2011 Oct 25.

PMID:
22028438
8.

An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.

Takahashi H, Mizuta T, Oeda S, Isoda H, Nakashita S, Kawaguchi Y, Izumi N, Hirai M, Kurose K, Iwane S, Eguchi Y, Kimura S, Anzai K, Ozaki I.

J Viral Hepat. 2013 Apr;20(4):e124-6. doi: 10.1111/jvh.12026. Epub 2012 Dec 10.

PMID:
23490380
9.

Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C).

Birerdinc A, Estep M, Afendy A, Stepanova M, Younossi I, Baranova A, Younossi ZM.

J Viral Hepat. 2012 Jun;19(6):414-22. doi: 10.1111/j.1365-2893.2011.01564.x. Epub 2011 Dec 7.

PMID:
22571903
10.

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.

Pineda-Tenor D, García-Álvarez M, Jiménez-Sousa MA, Vázquez-Morón S, Resino S.

J Transl Med. 2015 Oct 6;13:320. doi: 10.1186/s12967-015-0682-y.

11.

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes CN, Kumada H, Nakamura Y, Chayama K.

Gastroenterology. 2010 Oct;139(4):1190-7. doi: 10.1053/j.gastro.2010.06.071. Epub 2010 Jul 14.

PMID:
20637204
12.

Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms.

Galmozzi E, Facchetti F, Degasperi E, Aghemo A, Lampertico P.

J Virol Methods. 2013 Feb;187(2):271-3. doi: 10.1016/j.jviromet.2012.11.026. Epub 2012 Nov 29.

PMID:
23201294
13.

Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.

Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, Patel K, Thompson AJ, Rumi MG, D'Ambrosio R, Muir AJ, Colombo M.

J Viral Hepat. 2013 Dec;20(12):858-66. doi: 10.1111/jvh.12113. Epub 2013 Jun 24.

PMID:
24304455
14.

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG.

Gastroenterology. 2010 Oct;139(4):1181-9. doi: 10.1053/j.gastro.2010.06.016. Epub 2010 Jun 12.

15.

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.

Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Böcher WO, Mensa FJ.

PLoS One. 2015 Dec 9;10(12):e0144004. doi: 10.1371/journal.pone.0144004. eCollection 2015.

16.

Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment.

Tanaka Y.

Digestion. 2011;84 Suppl 1:50-5. doi: 10.1159/000333214. Epub 2011 Dec 2. Review.

PMID:
22156486
17.

The impact of human gene polymorphisms on HCV infection and disease outcome.

Schaefer EA, Chung RT.

Semin Liver Dis. 2011 Nov;31(4):375-86. doi: 10.1055/s-0031-1297926. Epub 2011 Dec 21. Review.

PMID:
22189977
18.

Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.

Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsuhashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M.

Hum Mol Genet. 2011 Sep 1;20(17):3507-16. doi: 10.1093/hmg/ddr249. Epub 2011 Jun 9.

PMID:
21659334
19.

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.

Aghemo A, Grassi E, Rumi MG, D'Ambrosio R, Galmozzi E, Degasperi E, Castaldi D, Soffredini R, Colombo M.

PLoS One. 2014 Apr 23;9(4):e95881. doi: 10.1371/journal.pone.0095881. eCollection 2014.

20.

Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.

Delvaux N, Costa VD, Costa MM, Villar LM, Coelho HS, Esberard EB, Flores PP, Brandão-Mello CE, Villela-Nogueira CA, Almeida AJ, Lampe E.

Mem Inst Oswaldo Cruz. 2015 Aug;110(5):636-43. doi: 10.1590/0074-02760150104. Epub 2015 Jul 7.

Supplemental Content

Support Center